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Abstract
Background: A large number of infertile couples are choosing Chinese herbal medicine (CHM) as an adjuvant therapy to
improve their success when undergoing in vitro fertilization (IVF). There is no systematic review to evaluate the impact of
CHM on the IVF outcomes.
Objective: To evaluate the effectiveness of CHM with concurrent IVF versus IVF alone on the outcomes of IVF and its safety.
Methods: The protocol of this study is registered at PROSPERO. Eligible RCTs searched from 8 databases which compared a
combination of CHM and IVF with IVF alone were included. Two authors independently selected studies, extracted data and
assessed methodological quality. Meta-analysis of RCTs was conducted if there was non-significant heterogeneity
(evaluated by I2 test) among trials. All statistical analysis was performed using RevMan 5.1 software.
Results: Twenty trials involving 1721 women were included in the meta-analysis. Three trials were evaluated as having an
unclear risk of bias. The remaining trials were evaluated as having a high risk of bias. Combination of CHM and IVF
significantly increases clinical pregnancy rates (OR 2.04, 95%CI 1.67 to 2.49, p,0.00001) and ongoing pregnancy rates (OR
1.91, 95%CI 1.17 to 3.10, p = 0.009). Use of CHM after embryo transfer had no better outcome in reducing the rate of ovarian
hyper stimulation syndrome (OR 0.39, 95%CI 0.14 to 1.11, p = 0.08).
Conclusions: This meta-analysis showed that combination of IVF and CHM used in the included trials improve IVF success,
however due to the high risk of bias observed with the trials, the significant differences found with the meta-analysis are
unlikely to be accurate. No conclusion could be drawn with respect to the reproductive toxicity of CHM. Further large
randomized placebo controlled trials are warranted to confirm these findings before recommending women to take CHM to
improve their IVF success.
Citation: Cao H, Han M, Ng EHY, Wu X, Flower A, et al. (2013) Can Chinese Herbal Medicine Improve Outcomes of In Vitro Fertilization? A Systematic Review and
?Meta-Analysis of Randomized Controlled Trials. PLoS ONE 8(12): e81650. doi:10.1371/journal.pone.0081650
Editor: Natalie Walker, The National Institute for Health Innovation, New Zealand
Received May 23, 2013; Accepted October 15, 2013; Published December 10, 2013
Copyright:  2013 Cao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: CHJ, HM, and LJP are supported by the Program for Innovative Research Team of Beijing University of Chinese Medicine (2011-CXTD-09), and the
project on research capacity building for TCM researchers (201207007). The funder is the employer for main investigators of this review. The funders had no role
in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Dr. Ernest HY Ng and Dr. Xiaoke Wu are Chinese herbal medicine practitioners. The authors have declared that no competing interests
exist.
* E-mail: Liujp@bucm.edu.cn
Introduction
Since the first live birth resulting from in vitro fertilization (IVF)
was reported in 1978 in the UK, the use of assisted reproductive
technology (ART) has doubled over the last decade [1]. In 2009,
total of 146,244 ART procedures were reported to the Center for
Disease Control (CDC) in United States, which resulted in 45,870
(31.4%) live births and 60,190 infants [2]. Though the number of
ART cycles has increased significantly, there is only a slight
improvement in the implantation and delivery rates over the years
[3].
A large number of infertile couples are choosing complementary
and alternative medicine (CAM) as an adjuvant therapy with the
intention of improving their chances of success when they undergo
IVF treatment [4,5]. Data from a prospective cohort study in the
United States shows that 17% of the couples had utilized herbal
therapy for infertility [6]. Another cross-sectional study [7] found
46% of Irish patients undergoing IVF admitted regular use of
CHM, with 38% of them having taken CHM in the 3-month
period prior to their attendance for treatment. Chinese herbal
medicine (CHM) has been used as an alternative to conventional
fertility treatments and appears to be effective in improving
pregnancy rates compared with western fertility drugs or IVF [8].
CHM may also increase the effectiveness of clomiphene citrate for
anovulation [9,10].
Prescription of CHM is usually based on the Chinese medicine
diagnostic patterns and follows a completely different rationale to
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conventional treatments [11]. However, biologically plausible
mechanisms of action have been suggested for CHM. According
to some preclinical studies, some specific herbal products appear to
improve the quality of oocytes [12,13], to enable a reduction in the
dose of gonadotrophin [14] and to increase endometrial blood
flow [15,16] and thereby increasing endometrial thickness [17].
They may promote early embryonic development, and possibly
improve the success rate of IVF [18,19].
There is no systematic review rigorously evaluating the impact
of additional concurrent CHM on the outcomes of IVF.
Therefore, the objective of this systematic review is to evaluate
the randomized controlled trials of the effectiveness of CHM with
concurrent IVF versus IVF alone on the outcomes of IVF and its
safety.
Methods
A protocol of this systematic review was registered and
published at PROSPERO, an international prospective register
of systematic review, on 17th December 2012 (NO.
CRD42012003479), which is available at the following website:
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=
CRD42012003479.
Inclusion Criteria of Studies
Randomized clinical trials (RCTs) with two parallel groups that
compared combinations of CHM and IVF with IVF alone were
included. One of the following outcomes had to be reported:
clinical pregnancy (defined as presence of at least one gestational
sac with or without a fetal pole), ongoing pregnancy (defined as
evidence of a gestational sac with fetal heart beats at twelve weeks),
and live birth (defined as delivery of a live fetus after 20 completed
weeks of gestation). There was no restriction on publication types
or language.
Search Strategy
We searched PubMed, the Cochrane CENTRAL Database,
EMBASE, China National Knowledge Infrastructure (CNKI),
Figure 1. Flow diagram.
doi:10.1371/journal.pone.0081650.g001
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VIP Database, Chinese Biomedical Database (CBM), and
Wanfang Database with following terms as abstract terms and
MeSH terms from inception to December 2012: (‘‘in vitro
fertilization’’ OR ‘‘fertilization in vitro’’ OR ‘‘intracytoplasmic
sperm injection’’ OR ‘‘assisted reproductive techniques’’ OR
‘‘assisted reproductive treatment’’ OR ‘‘oocytes’’ OR ‘‘egg
collection’’ OR ‘‘embryo transfer’’ OR ‘‘embryo implantation’’
OR ‘‘in vitro fertilization’’) and (‘‘herbal’’ OR ‘‘herb’’ OR
‘‘traditional Chinese medicine’’). Clinical trials were set as a
limitation for searching.
We also searched relevant ongoing trials from the US equivalent
Clinical Trials register (http://www.clinicaltrials.gov). All refer-
ences of the studies included and excluded were hand-searched for
additional relevant reports.
Study Selection, Data Extraction, and Methodological
Quality Assessment
Two authors (CHJ and HM) independently selected studies and
extracted data on patient characteristics, treatment details and
outcomes. Consensus was reached by discussion with the third
author (LJP) in case of discrepancy.
Two authors (CHJ and HM) independently assessed the
methodological quality of the included trials. The methodological
quality of RCTs was assessed according to the risk of bias tool
described in the Cochrane handbook for systematic reviews of
interventions [20]. Six elements were assessed: random sequence
generation, allocation concealment, blinding of outcome assessors,
incomplete outcome data, selective reporting and other bias.
Disagreements were resolved by discussion with the third author
(LJP). Due to the unequivocal outcome measurements (such as live
birth, clinical pregnancy), we thought that lack of blinding of
participants and personnel may not increase the risk of bias, thus
we removed this item from the original 7-item risk of bias table.
Data Analysis
All statistical analysis was performed using RevMan 5.1 (The
Cochrane Collaboration) software. Pooled odds ratio (OR) with
95% confidence interval (CI) of achieving a clinical pregnancy, live
birth, ongoing pregnancy and complications were measured for
women receiving CHM compared with those without CHM in
addition to IVF procedure. Heterogeneity of included trials was
evaluated statistically using the I2 test. Meta-analysis of RCTs was
conducted, if there was non-significant baseline difference of
participants, and if CHM intervention and control, and outcome,
and the statistical (according to I2) heterogeneity test showed no
significant difference among included trials. A funnel plot with ten
or more studies in an analysis was used to explore the possibility of
small study effects.
We conducted subgroup analyses to determine the evidence for
the administration of CHM at different times during IVF (before,
during and/or after the IVF). Sensitivity analyses were conducted
Table 1. Characteristics of 20 included trials on basic information.
Study ID
Participants
(original) Primary disease for infertility IVF Outcome
Risk of
bias
HG CG
Chang et al., 2011 35 35 ITO GnRH-a+ FR; HQER; CPR; AR; blighted ovum rate High
Deng et al., 2011 115 134 ITO; male factors GnRH-a+ ET; NTE; HQER; IR; CPR; OHSS High
*Deng et al., 2011a 41 41 ITO; male factors GnRH-a+ ET; NTE; HQER; IR; CPR; OHSS High
Gao and Du, 2012 30 28 non organic diseases infertility GnRH-a+ CPR; HQER; AR; OHSS; blighted ovum rate Unclear
*Gao et al., 2012 21 21 Unclear GnRH-a+ CPR; ET Unclear
Ge et al., 2010 101 106 ITO; male factors GnRH-a+ ET; HL; FR; NTE; IR; CPR; multiple birth rate; AR High
*Huang, 2012 82 80 Unclear Unclear CPR; AR High
Lei and Luo, 2011 20 21 ITO GnRH-a+ CPR; HQER; ET; NTE; IR; HL Unclear
Lian et al., 2006 33(36) 33(38) ITO GnRH-a+ HL; CPR; ET; HQER; FR High
Lian et al., 2008 36 28 POS GnRH-a+ HL; FR; HQER; BPR; CPR; OHSS High
Li, 2008 31 32 ITO; male factors GnRH-a+ ET; CPR; FR; HQER High
*Li, 2009 40 30 Unclear Unclear BPR; CPR High
Li et al., 2012 28 29 ITO Unclear FR; CPR High
Liu et al., 2008 42 40 endometriosis GnRH-a+ FR; HQER; CPR High
Li et al., 2008 10 10 endometriosis GnRH-a+/2 FR; CPR High
Sun et al., 2011 30(31) 31(33) fallopian tube obstruction GnRH-a+ ET; FR; HQER; NTE; CPR High
Teng and Lian, 2009 27 (30) 22 (30) deficiency of the kidney qi FET Chinese syndrome scores; NTE; HL; ET; CPR; IR High
Teng and Lian, 2006 42 38 ITO; deficiency of the kidney GnRH-a+ Chinese syndrome scores; FR; HQER; BPR; CPR High
Zhang et al., 2007 33 33 ITO GnRH-a+ CPR; embryo score High
Zhu et al., 2002 66(70) 69(70) ITO; endometriosis; male factors; GnRH-a+ FR; ET; NTE; IR; CPR High
*Women who accepted IVF and failed once (or more) before;
IVF: in vitro fertilization; HG: Herbal group; CG: Control group; ITO: infertility of tubal origin; POS: polycystic ovarian syndrome; GnRH-a: GnRH-a gonadotropin
releasing hormone agonist; GnRH-a+: GnRH-a long programme+corpus luteum (with fresh embryo transfer); GnRH-a2: GnRH-a short programme+corpus luteum
(with fresh embryo transfer); FET: frozen embryo transfer; FR: fertilization rate; HQER: high quality embryos rate; CPR: clinical pregnancy rate; AR: abortion rate; NTE:
No. of transferred embryos; IR: implantation rate; OHSS: ovarian hyper stimulation syndrome; OPR: ongoing pregnancy rate; ET: endometrial thickness; HL: hormone
levels.
doi:10.1371/journal.pone.0081650.t001
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to determine whether the conclusions would have differed if: 1)
eligibility were restricted to studies without high risk of bias; 2) a
fixed effect/random effect model had been adopted; 3) the
summary effect measure was relative risk rather than odds ratio.
Overall Quality of Body of Evidence: Summary of Findings
(SOF) Table
A SOF table was generated using GRADEPro software
(Version 3.2 for Windows). This table evaluated the overall
quality of the body of evidence for clinical pregnancy, live birth,
and ongoing pregnancy, using GRADE criteria (study limitations,
consistency of effect, imprecision, indirectness and publication
bias).
Results
Results of the Literature Search
The literature search process and study inclusion are shown in
Figure 1. Thirty trials met the inclusion criteria but ten studies
(Table S2 in File S1) were found to be non-randomized trials after
the respective authors were contacted by phone. Twenty trials
[14,16,17,21–37] were included. Two trials [31,33] had both a
published and an unpublished version: one as dissertation [38] and
the other as a conference abstract [39]. Three trials were reported
as dissertations [24,34,35]. One trial was reported as a conference
abstract [28]. The remaining 14 included trials were published in
scientific journals.
Characteristics of the Included Studies
All the included trials were conducted in China and published
in Chinese. In total 1721 women participated in 20 studies with
average 43 women per study group. The main causes for infertility
for the majority of women were tubal infertility, polycystic ovarian
syndrome, and endometriosis. Four trials [16,23,25,27] only
included women who had failed IVF at least once before. Detailed
information for the included studies is shown in Table 1.
One trial was on frozen embryo transfer, three trials did not
report the details of IVF, and the remaining 16 trials all employed
gonadotropin releasing hormone agonist (GnRH-a) on a long or
short protocol with fresh embryo transfer.
All 20 trials investigated whether CHM (including decoctions
and granules) could improve the clinical (or laboratory) outcomes
of IVF compared to IVF alone, but the timing of the CHM in
relation to IVF differed among the trials (Table 2). Intervention
groups in four trials [25,29,30,32] used CHM two or three months
before IVF, but none of them reported that individualized
prescription were used according to syndrome differentiation.
Nine trials reported that CHM was given during IVF, but three of
them [21,24,28] started using CHM on the first day of GnRH-a
injection, and the other six trials [14,31,33–36] started using
patent CHM (Erzhi Tiangui Granule) on the day they began
follicle stimulating hormone (FSH) injections. Three trials used
CHM in intervention groups after oocyte retrieval [37] or embryo
transfer [16,27]. Three trials [17,22,26] employed CHM during
and after IVF, and the remaining one trial [23] used CHM before,
during and after IVF. The composition of CHM tested in 20
included trials is showed in Table S1 in File S1. The most
commonly used herbs in the different herbal formulae included
Radix rehmanniae preparata (in 16 trials), Radix angelicae sinensis (in 15
trials), and Radix paeoniae alba (in 12 trials), which were accounted
for more than half of the trials. The use of these herbs was in
accordance with Chinese medicine theory, that is, to nourish yin
and tonify kidney, regulate qi and activate blood (Table 2).
Clinical pregnancy rate was reported in all 20 trials, ongoing
pregnancy rate or implantation rate were reported partially.
Adverse events, including miscarriage and ovarian hyper stimu-
lation syndrome (OHSS) were recorded in one third of the
included trials. Details of the results for outcome measurements in
the included trials were summarized under ‘Effect of CHM on the
outcomes of IVF’.
Methodological Qualities of the Included Studies
According to our pre-defined methodological quality criteria,
three included trials [24,25,28] should be classified as having
unclear risk of bias, and the remaining 17 trials were evaluated as
having a high risk of bias (Figure 2). All trials used a random
number table to generate random sequence, but only seven of
them reported that allocation to specific groups was performed by
a research nurse or postgraduate student. Regardless of whether
blinding of participants and personnel was used (as we pre-
specified), all of the trials did not provide details of blinding to
outcome assessors. Four trials (Table 1) reported the number of
dropouts, but intention-to-treat analysis was not employed in any
study. Other biases in the majority of trials were evaluated as high
risk due to insufficient information about sample size calculations,
Figure 2. Risk of bias graph - review authors’ judgments about each risk of bias item presented as percentages across all included
studies.
doi:10.1371/journal.pone.0081650.g002
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Table 3. Estimate effect of Chinese herbal medicine for improving clinical outcomes of patients with In Vitro Fertilization (IVF).
Study ID
Total No. of
participants
(embryo
implantation/pr
egnant) Interventions
Odds Ratio [95% CI],
M-H, Random model p value
1. Clinical pregnancy rate
1.1 herbal medicine before IVF
Gao et al., 2012 42 Periodic herbal decoction, one potion per day, twice
daily for 3 months
2.62 [0.64, 10.61]
Li et al., 2012 54 Hua Yu Powder 28 g, three times daily for 2 months 1.25 [0.42, 3.78]
Li et al., 2008 20 Qu Yu Jie Du Decoction 71 g, once daily for 3 months 3.86 [0.33, 45.57]
Liu et al., 2008 82 Qu Yu Jie Du Decoction 71 g, once daily for 3 months 2.72 [1.01, 7.32]
Pooling analysis 1.1 (I2=0%) 2.14 [1.14, 4.02] 0.02
1.2 herbal medicine during IVF
1.2.1 herbal medicine was given after GnRHa injection
Chang et al., 2011 70 Fixed herbal decoction 150 ml, twice daily until HCG injection 2.65 [0.99, 7.11]
Gao and Du, 2012 58 Xiao Yao Powder 150 ml, twice daily until HCG injection 2.33 [0.80, 6.85]
Lei and Luo, 2011 42 Cu Pai Luan Decoction, one portion daily until HCG injection 2.57 [0.71, 9.27]
Pooling analysis 1.2.1 (I2=0%) 2.51 [1.34, 4.74] 0.002
1.2.2 herbal medicine was given after FSH injection
Lian et al., 2006 66 Erzhi Tiangui Granule 3 g three times daily until HCG injection 2.94 [1.03, 8.39]
Lian et al., 2008 64 Erzhi Tiangui Granule 3 g three times daily until HCG injection 2.07 [0.67, 6.42]
Sun et al., 2011 61 Erzhi Tiangui Granule 3 g three times daily until HCG injection 3.15 [1.10, 8.99]
Teng and Lian, 2009 49 Erzhi Tiangui Granule 6 g three times daily until HCG injection 2.65 [0.70, 10.07]
Teng and Lian, 2006 80 Erzhi Tiangui Granule 6 g three times daily until HCG injection 2.55 [0.99, 6.53]
Zhang et al., 2007 66 Erzhi Tiangui Granule 10 g three times daily until HCG injection 2.74 [0.93, 8.08]
Pooling analysis 1.2.2 (I2=0%) 2.67 [1.72, 4.15] ,0.0001
Pooling analysis 1.2 (I2=0%) 2.62 [1.82, 3.76] ,0.00001
1.3 herbal medicine after IVF
1.3.1 herbal medicine was given immediately after oocyte retrieval
Zhu et al., 2002 135 Zi Shen Yu Tai Pills 6 g, three times daily for 14 days 1.99 [1.00, 3.98] 0.05
1.3.2 herbal medicine was given after embryo transfer
Huang, 2012 162 An Tai Mixture 250 ml, twice daily for 14 days 2.23 [1.19, 4.18]
Li, 2009 70 Adjusted Wenshen Yangxue Antai Decoction, one portion
for twice daily for 10–14 days
3.33 [1.06, 10.53]
Pooling analysis 1.3.2 (I2=0%) 2.44 [1.41, 4.24] 0.001
Pooling analysis 1.3 (I2=45%) 2.26 [1.47, 3.47] 0.00502
1.4 herbal medicine during and after IVF
Deng et al., 2011 249 Periodic herbal decoction, one potion per day, twice daily 1.67 [1.01, 2.76]
Ge et al., 2010 207 Periodic herbal decoction, one potion per day, twice daily 1.15 [0.67, 1.99]
Li, 2008 63 Adjusted Erzhi Pills and Siwu Decoction during IVF, Wenshen Yangxue
Antai
Decoction after IVF, one portion per day, twice daily
1.85 [0.65, 5.27]
Pooling analysis 1.4 (I2=0%) 1.45 [1.02, 2.06] 0.04
1.5 herbal medicine before, during and after IVF
Deng et al., 2011a 82 Periodic herbal decoction, one potion per day, twice daily 2.45 [1.01, 5.95] 0.05
Total meta-analysis 1 (I2=0%) 2.04 [1.67, 2.49] ,0.00001
2. ongoing pregnancy rate
2.1 herbal medicine before IVF
Liu et al., 2008 82 Qu Yu Jie Du Decoction 71 g, once daily for 3 months 2.04 [0.79, 5.25] 0.14
2.2 herbal medicine during IVF
Lian et al., 2008 64 Erzhi Tiangui Granule 3 g three times daily until HCG injection 1.34 [0.48, 3.79]
Teng and Lian, 2006 80 Erzhi Tiangui Granule 6 g three times daily until HCG injection 1.69 [0.69, 4.10]
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funding sources, baseline comparability and inclusion/exclusion
criteria of the participants.
Effect of CHM on the Outcomes of IVF
All the included trials compared CHM combined with IVF to
IVF alone for women with infertility and they all reported the
clinical pregnancy rate, which was assessed 4–5 weeks after
embryo transfer. Although the component of CHM was different
among the trials, the main treatment principles of the whole herbal
prescription were consistent and related to the stage at which
CHM was given during IVF (as showed in Table 2). All 20 trials
were included in meta-analysis (Table 3) and subgroup meta-
analysis was employed to address the effect of the timing of giving
CHM. A random effect model was used for pooling data even
though the I2 test showed no significant statistical heterogeneity
among trials.
i. Clinical pregnancy rate. Meta-analysis showed use of
CHM significantly increased the clinical pregnancy (OR 2.04,
95%CI 1.67 to 2.49, p,0.00001, 20 trials, I2=0%, Figure S1 in
File S1). The results of subgroup meta-analysis are consistent with
the overall meta-analysis.
A funnel plot analysis of 20 trials was performed to examine
outcome for the clinical pregnancy rate. The result showed
obviously asymmetry (Figure 3).
ii. Ongoing pregnancy rate. Four trials [14,16,32,35]
reported the ongoing pregnancy rate. Meta-analysis showed use
of CHM significantly improved ongoing pregnancies (OR 1.91,
95%CI 1.17 to 3.10, p= 0.009, 4 trials, I2=0%). Though the
results of subgroup meta-analysis showed inconsistent results of the
subgroup comparing giving CHM 3 months before (OR 2.04,
95%CI 0.79 to 5.25, p = 0.14, 1 trial) or during IVF until HCG
injection (OR 1.53, 95%CI 0.78 to 3.01, p = 0.22, 2 trials,
I2=0%).
iii. Implantation rate. The implantation rate gives the
percentage of embryos which are implanted compared to the
number of embryos transferred. Six trials [22,23–25,35,37]
reported implantation rates. A total of 1839 embryos were
transferred to 780 women with average 2.4 embryos per woman.
Meta-analysis showed use of CHM significantly increased the
Table 3. Cont.
Study ID
Total No. of
participants
(embryo
implantation/pr
egnant) Interventions
Odds Ratio [95% CI],
M-H, Random model p value
Pooling analysis 2.2 (I2=0%) 1.53 [0.78, 3.01] 0.22
2.3 herbal medicine after IVF
Li, 2009 70 Adjusted Wenshen Yangxue Antai Decoction, one portion for twice daily
for 10–14 days
2.97 [1.04, 8.49] 0.04
Total meta-analysis 2 (I2=0%) 1.91[1.17, 3.10] 0.009
3. implantation rate
3.1 herbal medicine during IVF
Gao and Du, 2012 58 (85) Xiao Yao Powder 150 ml, twice daily until HCG injection 2.50 [1.03, 6.11]
Teng and Lian, 2009 49 (120) Erzhi Tiangui Granule 6 g three times daily until HCG injection 2.40 [0.80, 7.24]
Pooling analysis 3.1 (I2=0%) 2.46 [1.23, 4.93] 0.01
3.2 herbal medicine after IVF
Zhu et al., 2002 135 (492) Zi Shen Yu Tai Pills 6 g, three times daily for 14 days 1.59 [1.02, 2.48]
3.3 herbal medicine during and after IVF
Deng et al., 2011 249 (489) Periodic herbal decoction, one potion per day, twice daily 1.51 [1.04, 2.20]
Ge et al., 2010 207 (428) Periodic herbal decoction, one potion per day, twice daily 1.51 [1.01, 2.25]
Pooling analysis 3.3 (I2=0%) 1.51 [1.15, 1.99] 0.003
3.4 herbal medicine before, during and after IVF
Deng et al., 2011a 82 (225) Periodic herbal decoction, one potion per day, twice daily 1.84 [1.03, 3.26] 0.04
Total meta-analysis 3 (I2=0%) 1.64 [1.33, 2.01] ,0.00001
4. adverse events
4.1 abortion rate (only included trials with herbal interventions post IVF)
Huang, 2012 (81) An Tai Mixture 250 ml, twice daily for 14 days 0.29 [0.09, 0.97] 0.04
4.2 OHSS rate
Chang et al., 2011 70 Fixed herbal decoction, 150 ml twice daily until HCG injection 3.09 [0.12, 78.41]
Deng et al., 2011 249 Periodic herbal decoction, one potion per day, twice daily 0.22 [0.05, 1.02]
Gao and Du, 2012 58 Xiao Yao Powder 150 ml, twice daily until HCG injection 0.30 [0.01, 7.69]
Lian et al., 2008 64 Erzhi Tiangui Granule 3 g three times daily until HCG injection 0.49 [0.08, 3.16]
Total meta-analysis 4.2 (I2=0%) 0.39 [0.14, 1.11] 0.08
CI: confidence interval; GnRH-a: GnRH-a gonadotropin releasing hormone agonist; FSH: follicle stimulating hormone; HCG: human chorionic gonadotrophin.
doi:10.1371/journal.pone.0081650.t003
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implantation rate (OR 1.64, 95%CI 1.33 to 2.01, p,0.00001, 6
trials, I2=0%). The results of subgroup meta-analysis were
consistent with the overall meta-analysis
iv. Miscarriage. Four trials [22,24–26] mentioned the
number of miscarriages (including blighted ovum rate). Total
meta-analysis showed CHM have no significant benefit in
reducing the miscarriage rate of patients undergoing IVF (OR
0.46, 95%CI 0.20 to 1.07, p = 0.07, 4 trials, I2=0%). However,
five of these eight trials which used CHM before or during IVF
showed no differences between groups for miscarriage, respec-
Figure 3. Funnel plot of Chinese herbal medicine plus IVF versus IVF alone on clinical pregnancy rate.
doi:10.1371/journal.pone.0081650.g003
Table 4. Summary of main findings of Chinese herbal medicine for improving clinical outcomes of patients with in vitro
fertilization.
Herbal medicine compared with no other treatment for women with in vitro fertilization
Patient or population: women with infertility
Settings: Department of gynecology
Intervention: herbal medicine combined with in vitro fertilization
Comparison: in vitro fertilization
Outcomes Illustrative comparative
risks* (95% CI)
Relative
effect
(95% CI)
No of
Participants
(studies)
Quality of the
evidence (GRADE)
Comments
Assumed
risk
[control]
Corresponding
risk [herbal
medicine]
clinical pregnancy
rate [4–5 weeks after
embryo transfer]
[362] per
1000
[532] per 1000
([477] to [590])
OR [2.04]
([1.68] to
[2.49])
[1721] ([20]) ›› low There were substantial and unclear or high risks
with the studies as well as publication bias
(according to funnel plot analysis)
ongoing pregnancy
rate [2 weeks after
embryo transfer]
[301] per
1000
[442] per 1000
([325] to [602])
OR [1.91]
([1.17] to
[3.10])
[296] ([3]) › very low This data must be interpreted with great caution
as the included trials are generally of poor quality
and there are small numbers of trials which
individually report a relatively small sample size
CI: Confidence interval; OR: Odds Ratio GRADE Working Group grades of evidence.
*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of herbal medicine (and its
95% CI).
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
doi:10.1371/journal.pone.0081650.t004
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tively. Only one trial [27] used CHM after IVF aimed on
protecting the fetus. Out of 81 pregnant women in this trial, five
women in the herbal group and nine women in the control group
miscarried, which showed use of CHM after embryo transfer was
effective in reducing the abortion rate (OR 0.29, 95%CI 0.09 to
0.97, p = 0.04).
v. OHSS. Six trials [14,21,22,24,33,37] mentioned OHSS
after IVF, but only four of them [14,21,22,24] reported the OHSS
rate. Meta analysis showed no difference whether CHM was used
before or after IVF on the number of women with OHSS (OR
0.39, 95%CI 0.14 to 1.11, p = 0.08, 4 trials, I2=0%).
vi. Other adverse events. No trial followed up the patients
beyond 10 gestational weeks, and the majority included trials
terminated the follow up 2–5 weeks after IVF. Due to the short-
term follow up duration, no trial reported adverse events relevant
to reproductive toxicity of CHM [40].
vii. Sensitivity analysis. Sensitivity analyses were included
and used to analyses whether the conclusions would have differed
if the summary effect measure was RR rather than OR. The
pooled results on clinical pregnancy rate (RR 1.47, 95%CI 1.32 to
1.63, p,0.00001, random model, 20 trials, I2=0%) and ongoing
pregnancy rate (RR 1.47, 95%CI 1.08 to 2.00, p = 0.01, random
model, 4 trials, I2=0%) were robust.
viii. Overall quality of body of evidence: summary of
finding table (Table 4). The results of 20 included trials
suggest a consistent positive effect for CHM on IVF outcomes
(Figure S1 in File S1). The potential clinical pregnancy rate of
women with IVF who used CHM with their IVF was 53.2%
(95%CI 47.7%–59.0%) compared to IVF alone (36.2%, as the
median risk across studies). However, the quality of evidence for
clinical pregnancy rate was ‘‘low’’. This occurred because only
Chinese literature was available, and there were high risks of bias
(according to methodological quality assessment and funnel plot
analysis) within the included studies.
The quality of evidence for ongoing pregnancy rate was all
rated as ‘‘very low’’ due to the high risk of bias within the trials and
the small sample sizes. Women who received combined CHM and
IVF treatment had 44.2% ongoing pregnancy rate (95%CI
32.5%–60.2%), when compared to the control group (30.1% as
the median risk across studies).
Discussion
Statement of Principal Findings
Meta-analysis of this study suggests that use of CHM (listed in
Table S1 in File S1) may improve the clinical pregnancy rate (from
36.2% to 53.2%), ongoing pregnancy rate and implantation rate of
the embryos for IVF, regardless of the time of concurrent
administration. The clinical pregnancy rate in the control group
(36.2%) and the average number of transferred embryos (2–3) are
similar to data reported elsewhere [SART: www.sart.org].
However, due to the high risk of bias observed with the trials,
the significant differences found with the meta-analysis are unlikely
to be accurate. Thus, the findings must be interpreted with great
caution as the included trials are generally of poor quality and
there are small numbers of trials with a relatively small sample size.
Strengths and Weaknesses of the Study
The methodological quality of included trials is generally poor.
Most did not used method of allocation concealment and there
was an inadequate method for dealing with data from women who
did not reach the stage of embryo transfer after IVF. Though we
evaluated the methodological quality regarding blinding to
patients and personnel, none of the included trials reported the
use of blinding clearly in the methods, consequently 85% of the
included trials were rated as ‘‘high risk of bias’’. Furthermore, due
to the insufficient duration of follow-up for all of the included
trials, live birth was not recorded and no trial reported the live
birth rate as the main outcome measurement.
There are also limitations of the review and meta-analysis itself.
Firstly, we searched the literature with general herb terms,
although an abstract search was used; this may not retrieve all
relevant studies, such as studies which used a specific CHM’s
name but were not indexed as TCM. All the included trials were
conducted and published in China and the funnel plot test showed
obviously asymmetry due to the potential publication bias and
small sample size of the included studies. Secondly, there was
substantial clinical heterogeneity among trials with respect to the
different prescriptions and usages of administration of CHM. Nine
fixed prescriptions were used in 16 of the included trials. Four
trials [22,23,25,26] employed herbal decoctions that were adjusted
according to the menstrual cycle based on fixed prescriptions
(Table S1 in File S1). Though we believe that an evaluation of the
whole system of CHM rather than just a particular remedy is a
valid form of analysis, and the core treatment principles of the
included trials were the same, complex herbal prescriptions
reduced the comparability of the included studies. Even if we
included all the trials in one meta-analysis regarding to the whole
system of CHM for improving clinical pregnancy rate of IVF, the
conclusion of this review could only be relied on the CHM which
had been tested in the included trials. Thirdly, only clinical
pregnancy rates and ongoing pregnancy rates were analyzed in
included trials but, live birth rate should be the primary outcome
for studies concerning this reproduction topic. No included trial
had sufficient duration of follow up to report live births. Finally,
only miscarriage and OHSS were reported in some of the included
trials but no trial reported other adverse events related to CHM or
congenital abnormalities of the fetuses, and because of the small
sample size of the trials we could not draw any conclusions about
the reproductive toxicity of CHM.
Meaning of the Study: Possible Explanations and
Implications for Clinicians and Policymakers
Although use of CHM seems to improve the clinical outcomes
for women undergoing IVF, subgroup analysis highlights the
impact of different outcomes related to variation in the timing of
administering CHM. One trial that used CHM only for 7 to 14
days after oocyte retrieval showed less effectiveness in increasing
the clinical pregnancy rate and the implantation rate of embryos
(p = 0.05). This indicates that giving CHM earlier and for a longer
duration may be more helpful in improving the clinical outcomes
of IVF and therefore the mechanism of CHM in IVF may involve
improving the quality of oocytes or embryos as suggested by some
experimental studies [12,14,28,34]. The results from three
individual studies show CHM given before and/or during IVF
may not reduce miscarriage, while application of CHM after
embryo transfer was effective in reducing the miscarriage rate.
The occurrence of this difference may be explained by the fact that
herbal prescriptions used after embryo transfer were usually
targeted at protecting the fetus [26], and involved herbals such as
An Tai (Calm the fetus) Mixture, which are listed in Table S1 in
File S1. Some studies also suggest that the rich content of zinc and
manganese, in some medicines may have an important effect on
the development of fetus [41]; other remedies may inhibit the
production of potentially destructive antibodies by regulating the
mother’s immunity and strengthening the immune-protective
action of the mother’s immune system on the fetus [42].
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Unanswered Questions and Future Research
No published systematic review has looked at the effect of CHM
in women undergoing IVF. In order to substantiate or refute these
preliminary findings, it is essential that more rigorous research is
carried out. True randomization, allocation concealment, blinding
(if appropriate), intention-to-treat analyses and a record of live
births should be routinely incorporated into research protocols.
Researchers should adhere to the CONSORT standards [http://
www.consort-statement.org] of trial reporting, and provide the
required methodological detail. If research into CHM can
incorporate these standards then its credibility will be enhanced
and the potential contribution of CHM to global healthcare can be
adequately evaluated.
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